Article info
PDFClinical science
Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec
- Correspondence to M. Dominik Fischer, Centre for Ophthalmology, Universitätsklinikum Tübingen Universitäts-Augenklinik, 72076 Tübingen, Baden-Württemberg, Germany; dominik.fischer{at}uni-tuebingen.de
Citation
Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec
Publication history
- Received December 28, 2021
- Accepted April 17, 2022
- First published May 24, 2022.
Online issue publication
October 18, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.